Octoplus Terug naar discussie overzicht

new members

1. [verwijderd] 23 april 2007 15:35

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   LATEST NEWS
   
   OctoPlus appoints new Scientific Advisory Board members
   22.04.2007, Leiden, the Netherlands
   
   OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that it has appointed three new members to its Scientific Advisory Board: professor Ab Osterhaus, professor Douwe Breimer and professor Peter van Brummelen. Current chairman professor Daan Crommelin and professor Wim Hennink will continue their work on the board. Three members will step down: professor Jan Feijen, professor Bert Leufkens and dr. Paul Morrison.
   
   Prof.dr. Ab Osterhaus is a leading authority in the area of virology and brings thirty years of experience in animal and human virology to OctoPlus’ Scientific Advisory Board. Professor Osterhaus started his career in Utrecht (the Netherlands) where he graduated with distinction at the faculty of veterinary sciences and received his Ph.D. degree with distinction in 1978. He has been instrumental in scientific progress made at the RIVM (the Dutch National Institute for Public Health and the Environment) and Erasmus Medical Center in Rotterdam. He has written over 650 academic articles, created biotech companies and held several editorial positions.
   
   Prof.dr. Douwe Breimer is professor of pharmacology at Leiden University since 1975. He was Rector Magnificus of Leiden University from 2001 to 2007. He is (co)-author of more than 500 scientific papers in the areas of pharmacology, biopharmaceutics, pharmacokinetics and drug metabolism. Professor Breimer received several scientific distinctions including seven honorary doctorates. He is Chairman of the Board of Directors of venture capital firm Life Sciences Partners and was a member of the national Innovation Platform of the Netherlands.
   
   Prof.dr. Peter van Brummelen is an independent drug development consultant and board member of several biotech companies. From 1988 to 2003 he served in executive positions at Yamanouchi Europe, Solvay Pharmaceuticals and Hoffmann La Roche, where he contributed substantially to the successful development of various new drugs in different therapeutic classes. Professor Van Brummelen has an M.D. and Ph.D. from Leiden University. He was also a board certified specialist in internal medicine and held various positions at the universities of Leiden and Basel (Switzerland). He (co-)authored over 200 scientific publications.
   
   “We are pleased to welcome these three new members to our Scientific Advisory Board and look forward to their valuable input to OctoPlus in the future,” comments Joost Holthuis, CEO of OctoPlus. “We would like to acknowledge professor Feijen, professor Leufkens and dr. Morrison for their contribution to the success of our company.”